Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: while there is optimism in product development and partnerships, financial metrics show declining cash flow and net loss. The guidance is cautious, with some positive outlooks, but uncertainties in key markets like China and the Americas persist. The Q&A reveals optimism in certain areas, but management's vague responses on growth and market challenges add uncertainty, balancing positive developments. Overall, the sentiment remains neutral as positive and negative factors offset each other.
Key Financial Performance
Net Sales Net sales for Q3 2025 were approximately $653 million, a 0.5% increase on a reported basis compared to $650 million in Q3 2024. On a currency-neutral basis, this represents a 1.7% year-over-year decrease, driven by both the Life Science and Clinical Diagnostics segments.
Life Science Segment Sales Sales were $262 million in Q3 2025 compared to $261 million in Q3 2024, essentially flat on a reported basis and a 1.5% decrease on a currency-neutral basis. The decline was driven by constrained academic research and biotech funding environments.
Process Chromatography Business Experienced strong double-digit growth year-over-year in Q3 2025 due to the timing of customer orders. However, core Life Science segment revenue decreased 6% year-over-year and 7.8% on a currency-neutral basis, reflecting ongoing softness in academic research and biotech end markets and tough comparisons due to large one-time orders in the prior year.
Clinical Diagnostics Segment Sales Sales were approximately $391 million in Q3 2025 compared to $389 million in Q3 2024, a 0.6% increase on a reported basis and a 1.8% decrease on a currency-neutral basis. The decrease was primarily due to lower reimbursement rates for diabetes testing in China.
Gross Margin Reported GAAP gross margin for Q3 2025 was 52.6%, compared to 54.8% in Q3 2024. Non-GAAP gross margin was 53.5% versus 55.6% in the prior year. The decrease was due to higher material costs and reduced fixed manufacturing absorption.
SG&A Expense SG&A expense for Q3 2025 was $207 million (31.7% of sales) compared to $200 million (30.8% of sales) in Q3 2024. Non-GAAP SG&A spend was $202 million versus $197 million in the prior year. The increase was due to higher employee-related costs.
R&D Expense R&D expense for Q3 2025 was $71 million (10.9% of sales) compared to $91 million (14% of sales) in Q3 2024. Non-GAAP R&D spend was $70 million versus $91 million in the prior year. The decrease was primarily due to higher in-process R&D charges associated with an acquisition in Q3 2024.
Operating Income Operating income for Q3 2025 was approximately $65 million (10% of sales), flat versus Q3 2024 on both a dollar and percentage basis. Non-GAAP operating margin was 11.8% compared to 11.3% in Q3 2024, reflecting proactive cost actions and net reductions in IP R&D expense.
Net Income Reported net loss for Q3 2025 was $342 million or $12.70 per diluted share, primarily due to a $398 million loss from the change in fair market value of equity security holdings. Non-GAAP net income was $61 million or $2.26 per diluted share, compared to $56 million or $2.02 per diluted share in Q3 2024.
Cash Flow Net cash generated from operating activities in Q3 2025 was $121 million compared to $164 million in Q3 2024. Free cash flow for Q3 2025 was $89 million, compared to $123 million in Q3 2024. The decrease was due to lower operating cash flow and higher capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Droplet Digital PCR (ddPCR) strategy: Completed global sales training on new QX platforms; positive customer receptivity, especially in the entry-level segment; sales funnel building despite extended selling cycles.
ddPCR-based diagnostic strategy: Expanded through partnerships with Gencurix and Biodesix. Gencurix partnership makes Bio-Rad the exclusive distributor of Droplex oncology testing kits in Europe. Biodesix partnership expands access to biomarker testing for advanced breast cancer.
Process Chromatography: Strong double-digit growth year-over-year due to timing of customer orders; expected high teens growth for 2025.
Geographic Sales Performance: Currency-neutral sales decreased in the Americas but increased in Asia Pacific and EMEA for Life Science segment. Clinical Diagnostics saw decreased sales in Asia Pacific but increased in the Americas and EMEA.
Cost Management: Disciplined cost management and tight control of discretionary spending led to margin outperformance.
Lean Initiatives: Operational teams advanced lean initiatives and maintained cost discipline.
Share Buyback Program: Purchased 212,578 shares for $53 million in Q3 2025; year-to-date buybacks total $296 million with $285 million remaining for future buybacks.
Guidance for 2025: Maintained full-year outlook with flat to 1% currency-neutral revenue growth; gross margin expected at 53.5%-54.5% and operating margin at 12%-13%.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Reimbursement rate headwind in China: Lower reimbursement rates for diabetes testing in China have negatively impacted sales in the Clinical Diagnostics segment. This challenge is expected to annualize in the fourth quarter, but the soft macro environment in China could continue to dampen demand for clinical diagnostics products.
Softness in academic research and biotech funding: Ongoing uncertainty and cautious budgeting among research customers have led to weak instrument demand and softness in consumables. This has negatively impacted the Life Science segment, with constrained academic research and biotech funding environments being key contributors.
Process chromatography revenue volatility: While process chromatography experienced strong growth in Q3, revenue is expected to decline sequentially and year-over-year in Q4 due to the timing of customer orders. This volatility poses a challenge to consistent revenue generation.
Higher material costs and reduced fixed manufacturing absorption: These factors have contributed to a decrease in gross margins, impacting overall profitability.
Extended selling cycles for new products: The broader funding climate has led to extended selling cycles for new systems, such as the QX platforms in the Droplet Digital PCR strategy, potentially delaying revenue realization.
Soft macro environment in China: Beyond reimbursement challenges, the overall soft macroeconomic conditions in China could further dampen demand for products in the Clinical Diagnostics segment.
Uncertainty surrounding NIH budget and U.S. government shutdown: Research customers remain cautious with spending due to uncertainties surrounding the final NIH budget and the potential U.S. government shutdown, which could delay recovery in the academic segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Life Science Segment Revenue: Modest revenue improvement anticipated in the fourth quarter of 2025. No expected budget flush as research customers remain cautious due to uncertainties surrounding the final NIH budget and U.S. government shutdown. Recovery for the academic segment is expected to take time, with a cautious outlook heading into 2026. Gradual improvement anticipated with biotech customers.
Diagnostics Segment Revenue: Expected to return to growth in the fourth quarter of 2025 as the China reimbursement headwind annualizes and revenue from the quality controls portfolio is realized. No additional reimbursement challenges in China are anticipated for 2026, but a soft macro environment in the region could dampen demand for clinical Diagnostics products.
Process Chromatography Business: Fourth quarter revenue expected to be lower sequentially and year-over-year due to timing of customer orders. Full year 2025 growth outlook revised to high teens from prior low double-digit growth outlook.
Margins: Slight step-up in fourth quarter gross margin anticipated, driven by revenue mix. Sequential improvement in operating margins expected by at least 80 basis points in Q4 2025. Full year 2025 non-GAAP gross margin outlook remains at 53.5% to 54.5%, and operating margin outlook remains at 12% to 13%.
Free Cash Flow: Full year 2025 free cash flow expected to be approximately $310 million to $330 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: During the third quarter, we purchased 212,578 shares of our stock for a total cost of $53 million or an average purchase price of approximately $249 per share. Year-to-date, we have retired 1.2 million shares through our buyback program, at a total cost of approximately $296 million. We will continue to be opportunistic with share repurchases and still have approximately $285 million available for additional buybacks under the current Board authorized program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the expectations for 4Q, including the government shutdown and process chrome pull forward?
A:Life Sciences and Diagnostics are expected to see a slight uptick. Process chromatography presents a headwind, but ddPCR is expected to provide strength. Diagnostics quality controls are expected to jump based on lot leases. Demand in October was on plan, and Clinical Diagnostics and Life Sciences are off to a good start this quarter.
Q:Any initial thoughts on the market in 2026, including China diagnostics, academic government, and revenue moving pieces?
A:Academic in the U.S. remains cautious, depending on the NIH budget. Instruments are most affected, while consumables are stable. China remains uncertain, with no significant impact from VBP or DRG. Biotech is expected to gradually improve, and process chromatography is expected to normalize to high single-digit growth.
Q:What are your thoughts on digital PCR and its market outlook for next year?
A:The commercial team is excited, with good reception of new products and expanded assays. Partnerships are expected to provide upside in diagnostics. There is optimism about pipeline development and broader market recovery.
Q:Does the total year guidance imply 1% to 5% organic growth for Q4, and how does the government shutdown factor into this?
A:The guidance contemplates the government shutdown and assumes sequential improvement in Life Sciences and Diagnostics from Q3 to Q4. The full-year top-line guidance is 0% to 1%, with operating margins expected to improve sequentially from Q3 to Q4.
Q:Does process chromatography for 2026 reflect market normalization, given its historical volatility?
A:Volatility remains due to customer demand fluctuations, but normalization to high single-digit growth is expected as there are no easy comparisons from 2025 to 2026.
Q:Can you quantify the diabetes pricing headwind in China for the quarter?
A:Last year's Q4 had a mid-single-digit headwind from price cuts and an additional low to mid-single-digit headwind from channel adjustments.
Q:Any color on ddPCR instruments versus consumables in Q3, and was integration disruptive to revenues?
A:Integration was not disruptive. Consumables were slow in Q3 but are expected to rebound in Q4. The pipeline is growing, and instrumentation is expected to recover in Q4 and into 2026.
Q:Can margins expand in 2026 with low single-digit revenue growth, and what are the moving parts in the P&L?
A:Margin expansion is possible with operational improvements, logistics enhancements, supply chain leverage, and higher productivity in R&D and other functional areas.
Q:Why do you not expect China diagnostic headwinds in 2026 despite VBP concerns?
A:VBP has not significantly affected the company. Strength in quality controls and potential macroeconomic improvements in China are expected to offset broader headwinds.
Q:What is causing the pressure in the Americas Life Sciences market, and how does it compare to other regions?
A:The pressure is due to budget tightening in large academic institutions and a general slowdown. EMEA and regions outside China and Korea remain strong, with the U.S. facing the most pressure.
Q:What is the outlook for digital PCR, including QX Continuum and Stilla, and their revenue contribution for the second half?
A:Revenue contribution is expected in the single millions. Both QX Continuum and Stilla have strong customer interest, with the lower-end QX model being particularly competitive.
Q:What is the reason for the slowdown in the Americas Life Sciences market, and how does it affect Q4 expectations?
A:The slowdown is attributed to budget tightening and a wait-and-see approach by customers. Despite this, Life Sciences overall is expected to grow in Q4, with process chromatography taking a step down.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific magnitude of the range for Q4 organic growth (1% to 5%) and the exact impact of the government shutdown. Additionally, they did not provide precise details on the extent to which digital PCR is being written into budgets or the exact magnitude of tough comps in the Americas Life Sciences market.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG order
Bio Rad
CLIA lab
Conference webcast
Desiree conference
Diagnostics segment
ESR assay
Europe footprint
Officer today
PCR sale
Rad Investors
Rad distributor
Rad result
Relations review
Relations section
Roop result
access biomarker
addition nonreoccurring
adoption ddPCR
agility team
area reimbursement
assay CLIA
biomarker testing
budget sentiment
cancer ESR
change equity
chromatography softness
climate ddPCR
consensus testament
consumables cost
control spending
cost discipline
customer receptivity
cycle funding
ddPCR cancer
discipline agility
progress
today Bio
BIO Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-19
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals mixed factors: modest revenue growth, strong ddPCR performance, and strategic M&A focus are positives, yet geopolitical challenges and soft consumable sales are concerns. Unclear management responses and mid-single-digit organic growth decline further neutralize sentiment. The market may react cautiously, but with no drastic movements expected.
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call presents a mixed picture: modest revenue growth in diagnostics and improved free cash flow contrast with declining margins and net income. The Q&A reveals cautious management guidance and uncertainties in process chromatography. Despite strong growth in ddPCR and cash reserves, the lack of buyback and management's vague responses temper optimism. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture: while there is optimism in product development and partnerships, financial metrics show declining cash flow and net loss. The guidance is cautious, with some positive outlooks, but uncertainties in key markets like China and the Americas persist. The Q&A reveals optimism in certain areas, but management's vague responses on growth and market challenges add uncertainty, balancing positive developments. Overall, the sentiment remains neutral as positive and negative factors offset each other.
BIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
